Assessing anticoagulation practice patterns in patients on durable mechanical circulatory support devices: An international survey

Douglas L. Jennings, Edward T. Horn, Haifa Lyster, Anthony L. Panos, Jeffrey J. Teuteberg, Hans B. Lehmkuhl, Alexandra Perez, Michael A. Shullo

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Anticoagulation in mechanical circulatory support (MCS) patients dictated by local practice, and therefore uniform standards for management are lacking. To characterize the worldwide variance in anticoagulation and antiplatelet therapy in patients with MCS devices, a 42 item survey was created and distributed electronically in August 2014. The survey assessed the center-perceived thromboembolic risk (minimal, low, moderate, or high) and characterized the antiplatelet and anticoagulant strategies for the Thoratec HeartMate II (HMII) and HeartWare HVAD (HVAD). A total of 83/214 centers (39%) responded: North America (60/152), Europe (18/50), Australia (2/4), and Asia (3/8). Although the most common target international normalized ratio (INR) was 2-3 for both devices, significant variability exists. Anticoagulation intensity tended to be lower with the HMII, with more centers targeting INR values of less than 2.5. Aspirin monotherapy was the most common antiplatelet regimen; however, the HVAD patients were more likely to be on daily aspirin doses over 100 mg. In addition, parenteral bridging was more frequent with the HVAD device. While 43.8% of respondents indicated an increase in the perceived risk of HMII device thrombosis in 2014, intensification of anticoagulation (22%) or antiplatelet (11%) therapy was infrequent. Our findings verify the wide variety of anticoagulation practice patterns between MCS centers.

Original languageEnglish (US)
Pages (from-to)28-32
Number of pages5
JournalASAIO Journal
Volume62
Issue number1
DOIs
StatePublished - 2016

Fingerprint

Aspirin
Equipment and Supplies
International Normalized Ratio
Anticoagulants
North America
Thrombosis
Surveys and Questionnaires
Therapeutics

Keywords

  • Anticoagulation
  • Device Thrombosis
  • Mechanical Circulatory Support
  • Practice Variance
  • Stroke

ASJC Scopus subject areas

  • Biophysics
  • Biomaterials
  • Bioengineering
  • Biomedical Engineering
  • Medicine(all)

Cite this

Jennings, D. L., Horn, E. T., Lyster, H., Panos, A. L., Teuteberg, J. J., Lehmkuhl, H. B., ... Shullo, M. A. (2016). Assessing anticoagulation practice patterns in patients on durable mechanical circulatory support devices: An international survey. ASAIO Journal, 62(1), 28-32. https://doi.org/10.1097/MAT.0000000000000274

Assessing anticoagulation practice patterns in patients on durable mechanical circulatory support devices : An international survey. / Jennings, Douglas L.; Horn, Edward T.; Lyster, Haifa; Panos, Anthony L.; Teuteberg, Jeffrey J.; Lehmkuhl, Hans B.; Perez, Alexandra; Shullo, Michael A.

In: ASAIO Journal, Vol. 62, No. 1, 2016, p. 28-32.

Research output: Contribution to journalArticle

Jennings, DL, Horn, ET, Lyster, H, Panos, AL, Teuteberg, JJ, Lehmkuhl, HB, Perez, A & Shullo, MA 2016, 'Assessing anticoagulation practice patterns in patients on durable mechanical circulatory support devices: An international survey', ASAIO Journal, vol. 62, no. 1, pp. 28-32. https://doi.org/10.1097/MAT.0000000000000274
Jennings, Douglas L. ; Horn, Edward T. ; Lyster, Haifa ; Panos, Anthony L. ; Teuteberg, Jeffrey J. ; Lehmkuhl, Hans B. ; Perez, Alexandra ; Shullo, Michael A. / Assessing anticoagulation practice patterns in patients on durable mechanical circulatory support devices : An international survey. In: ASAIO Journal. 2016 ; Vol. 62, No. 1. pp. 28-32.
@article{da6a8b15c81842b894243814d3e2edd4,
title = "Assessing anticoagulation practice patterns in patients on durable mechanical circulatory support devices: An international survey",
abstract = "Anticoagulation in mechanical circulatory support (MCS) patients dictated by local practice, and therefore uniform standards for management are lacking. To characterize the worldwide variance in anticoagulation and antiplatelet therapy in patients with MCS devices, a 42 item survey was created and distributed electronically in August 2014. The survey assessed the center-perceived thromboembolic risk (minimal, low, moderate, or high) and characterized the antiplatelet and anticoagulant strategies for the Thoratec HeartMate II (HMII) and HeartWare HVAD (HVAD). A total of 83/214 centers (39{\%}) responded: North America (60/152), Europe (18/50), Australia (2/4), and Asia (3/8). Although the most common target international normalized ratio (INR) was 2-3 for both devices, significant variability exists. Anticoagulation intensity tended to be lower with the HMII, with more centers targeting INR values of less than 2.5. Aspirin monotherapy was the most common antiplatelet regimen; however, the HVAD patients were more likely to be on daily aspirin doses over 100 mg. In addition, parenteral bridging was more frequent with the HVAD device. While 43.8{\%} of respondents indicated an increase in the perceived risk of HMII device thrombosis in 2014, intensification of anticoagulation (22{\%}) or antiplatelet (11{\%}) therapy was infrequent. Our findings verify the wide variety of anticoagulation practice patterns between MCS centers.",
keywords = "Anticoagulation, Device Thrombosis, Mechanical Circulatory Support, Practice Variance, Stroke",
author = "Jennings, {Douglas L.} and Horn, {Edward T.} and Haifa Lyster and Panos, {Anthony L.} and Teuteberg, {Jeffrey J.} and Lehmkuhl, {Hans B.} and Alexandra Perez and Shullo, {Michael A.}",
year = "2016",
doi = "10.1097/MAT.0000000000000274",
language = "English (US)",
volume = "62",
pages = "28--32",
journal = "ASAIO Journal",
issn = "1058-2916",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - Assessing anticoagulation practice patterns in patients on durable mechanical circulatory support devices

T2 - An international survey

AU - Jennings, Douglas L.

AU - Horn, Edward T.

AU - Lyster, Haifa

AU - Panos, Anthony L.

AU - Teuteberg, Jeffrey J.

AU - Lehmkuhl, Hans B.

AU - Perez, Alexandra

AU - Shullo, Michael A.

PY - 2016

Y1 - 2016

N2 - Anticoagulation in mechanical circulatory support (MCS) patients dictated by local practice, and therefore uniform standards for management are lacking. To characterize the worldwide variance in anticoagulation and antiplatelet therapy in patients with MCS devices, a 42 item survey was created and distributed electronically in August 2014. The survey assessed the center-perceived thromboembolic risk (minimal, low, moderate, or high) and characterized the antiplatelet and anticoagulant strategies for the Thoratec HeartMate II (HMII) and HeartWare HVAD (HVAD). A total of 83/214 centers (39%) responded: North America (60/152), Europe (18/50), Australia (2/4), and Asia (3/8). Although the most common target international normalized ratio (INR) was 2-3 for both devices, significant variability exists. Anticoagulation intensity tended to be lower with the HMII, with more centers targeting INR values of less than 2.5. Aspirin monotherapy was the most common antiplatelet regimen; however, the HVAD patients were more likely to be on daily aspirin doses over 100 mg. In addition, parenteral bridging was more frequent with the HVAD device. While 43.8% of respondents indicated an increase in the perceived risk of HMII device thrombosis in 2014, intensification of anticoagulation (22%) or antiplatelet (11%) therapy was infrequent. Our findings verify the wide variety of anticoagulation practice patterns between MCS centers.

AB - Anticoagulation in mechanical circulatory support (MCS) patients dictated by local practice, and therefore uniform standards for management are lacking. To characterize the worldwide variance in anticoagulation and antiplatelet therapy in patients with MCS devices, a 42 item survey was created and distributed electronically in August 2014. The survey assessed the center-perceived thromboembolic risk (minimal, low, moderate, or high) and characterized the antiplatelet and anticoagulant strategies for the Thoratec HeartMate II (HMII) and HeartWare HVAD (HVAD). A total of 83/214 centers (39%) responded: North America (60/152), Europe (18/50), Australia (2/4), and Asia (3/8). Although the most common target international normalized ratio (INR) was 2-3 for both devices, significant variability exists. Anticoagulation intensity tended to be lower with the HMII, with more centers targeting INR values of less than 2.5. Aspirin monotherapy was the most common antiplatelet regimen; however, the HVAD patients were more likely to be on daily aspirin doses over 100 mg. In addition, parenteral bridging was more frequent with the HVAD device. While 43.8% of respondents indicated an increase in the perceived risk of HMII device thrombosis in 2014, intensification of anticoagulation (22%) or antiplatelet (11%) therapy was infrequent. Our findings verify the wide variety of anticoagulation practice patterns between MCS centers.

KW - Anticoagulation

KW - Device Thrombosis

KW - Mechanical Circulatory Support

KW - Practice Variance

KW - Stroke

UR - http://www.scopus.com/inward/record.url?scp=84952714706&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84952714706&partnerID=8YFLogxK

U2 - 10.1097/MAT.0000000000000274

DO - 10.1097/MAT.0000000000000274

M3 - Article

AN - SCOPUS:84952714706

VL - 62

SP - 28

EP - 32

JO - ASAIO Journal

JF - ASAIO Journal

SN - 1058-2916

IS - 1

ER -